Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
Impact in
- Oncology 146
Classified as
- Journal
- PubMed
In The Last Decade
doi.org/w88769270 →Countries where authors are citing Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
This map shows the geographic impact of Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. more than expected).
Fields of papers citing Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
This network shows the impact of Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously..
About Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
This paper, published in 2003, received 525 indexed citations . Written by Wm. Kevin Kelly, Victoria M. Richon, Owen A. O’Connor, Tracy Curley, William P. Tong, Mark Klang, Lawrence B. Schwartz, Eddie Rosa, Marija Drobnjak and Judy H. Chiao covering the research area of Molecular Biology, Oncology and Physiology. It is primarily cited by scholars working on Molecular Biology (476 citations), Oncology (146 citations), Hematology (44 citations), Pathology and Forensic Medicine (39 citations) and Immunology (35 citations). Published in PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/w88769270.